Read by QxMD icon Read

C-11 choline/PET

David M Schuster, Cristina Nanni, Stefano Fanti
Conventional imaging of prostate cancer has limitations related to the frequently indolent biology of the disease. PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Radiotracers that are in use or under investigation for targeting salient features of prostate cancer include those directed to glucose, choline, acetate, prostate-specific membrane antigen, bombesin, and amino acids...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Francesco Ceci, Paolo Castellucci, Paola Mapelli, Elena Incerti, Maria Picchio, Stefano Fanti
The aim of this review is to report on the value of (11)C-choline PET imaging as a diagnostic procedure for metastasis-directed therapies. Furthermore, the role of (11)C-choline PET/CT as a diagnostic tool for monitoring castration-resistant prostate cancer patients treated with systematic therapy is assessed. Finally, the role of (11)C-choline PET/CT in the prediction of survival in both castration-resistant prostate cancer patients and hormone-naïve patients is investigated.
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Sascha Nitsch, Oliver W Hakenberg, Martin Heuschkel, Desiree Dräger, Guido Hildebrandt, Bernd J Krause, Sarah M Schwarzenböck
Early diagnosis and adequate staging are crucial for the choice of adequate treatment in prostate cancer (PC). Morphologic and functional imaging modalities, such as CT and MRI, have had limited accuracy in the diagnosis and nodal staging of PC. Molecular PET/CT imaging with (11)C- or (18)F-choline-labeled derivatives is increasingly being used, but its role in the diagnosis and initial staging of PC is controversial because of limitations in sensitivity and specificity for the detection of primary PC. For T staging, functional MRI is superior to (11)C- or (18)F-choline PET/CT...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Marcin Szydło, Michał Jadwiński, Agnieszka Chmura, Kamil Gorczewski, Maria Sokół
[(11)C]-choline is an effective PET tracer used for imaging of neoplastic lesions and metastases of the prostate cancer. However, its production can be a challenge for manufacturers, as it has not yet been described in Polish or European pharmacopoeia. In this study the technical aspects of [(11)C]-choline production are described and detailed process parameters are provided. The quality control procedures for releasing [(11)C]-choline as solutio iniectabilis are also presented. The purity and quality of the radiopharmaceutical obtained according to the proposed method were find to be high enough to safely administrate the radiopharmaceutical to patients...
2016: Contemporary Oncology Współczesna Onkologia
S Piel, M Kreuter, F Herth, H-U Kauczor, C-P Heußel
CLINICAL/METHODICAL ISSUE: Granulomas as signs of specific inflammation of the lungs are found in various diseases with pulmonary manifestations and represent an important imaging finding. STANDARD RADIOLOGICAL METHODS: The standard imaging modality for the work-up of granulomatous diseases of the lungs is most often thin-slice computed tomography (CT). There are a few instances, e. g. tuberculosis, sarcoidosis and silicosis, where a chest radiograph still plays an important role...
October 2016: Der Radiologe
Daniar K Osmonov, Alexey V Aksenov, David Trick, Carsten M Naumann, Moritz F Hamann, Amr Abou Faddan, Klaus-Peter Jünemann
BACKGROUND: The aim was to evaluate cancer-specific survival (CSS) and overall survival (OS) in patients with prostate cancer (PCa) recurrence who underwent salvage extended pelvic lymph node dissection (ePLND), taking into consideration pre- and postoperative androgen deprivation therapy (ADT). METHODS: Salvage ePLND was performed in a cohort of 54 patients with PCa recurrence, and data from 45 patients were analyzed. The indications for salvage ePLND were biochemical recurrence (BCR) of PCa and suspect findings on (11)C-choline PET/CT...
2016: BMC Urology
Johannes Schwenck, Hansjoerg Rempp, Gerald Reischl, Stephan Kruck, Arnulf Stenzl, Konstantin Nikolaou, Christina Pfannenberg, Christian la Fougère
PURPOSE: Prostate-specific membrane antigen (PSMA) is expressed ubiquitously on the membrane of most prostate tumors and its metastasis. While PET/CT using (11)C-choline was considered as the gold standard in the staging of prostate cancer, PET with radiolabelled PSMA ligands was introduced into the clinic in recent years. Our aim was to compare the PSMA ligand (68)Ga-PSMA-11 with (11)C-choline in patients with primary and recurrent prostate cancer. METHODS: 123 patients underwent a whole-body PET/CT examination using (68)Ga-PSMA-11 and (11)C-choline...
August 24, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Martin Krakauer, Andreas Kjaer, Finn N Bennedbæk
Preoperative localisation of the diseased parathyroid gland(s) in primary hyperparathyroidism (PHP) is a prerequisite for subsequent minimally invasive surgery. Recently, as alternatives to conventional sestamibi parathyroid scintigraphy, the (11)C-based positron emission tomography (PET) tracers methionine and choline have shown promise for this purpose. We evaluated the feasibility of using the (18)F-based PET tracer fluoroethyl-l-tyrosine (FET), as the longer half-life of (18)F makes it logistically more favourable...
August 17, 2016: Diagnostics
Joshua J Morigi, S Fanti, D Murphy, Michael S Hofman
PURPOSE OF REVIEW: PET/CT imaging in men with prostate cancer (PCa) is rapidly growing as clinicians are becoming aware of its possible fundamental role in the diagnostic flow chart of these patients. As this technology becomes more available worldwide, a considerable number of scientific studies are focusing on specific clinical scenarios and novel PET radiopharmaceuticals that might assist improving early diagnosis and shifting to a truly tailored treatment for PCa. This review focuses on the most recent and important publications in PET/CT imaging of PCa...
September 2016: Current Opinion in Urology
Ilya Sobol, Harras B Zaid, Rimki Haloi, Lance A Mynderse, Adam T Froemming, Val J Lowe, Brian J Davis, Eugene D Kwon, R Jeffrey Karnes
PURPOSE: We identify sites and patterns of cancer recurrence in patients with post-prostatectomy biochemical relapse using (11)C-choline positron emission tomography/computerized tomography and endorectal coil multiparametric magnetic resonance imaging. MATERIALS AND METHODS: Between January 2008 and June 2015, 2,466 men underwent choline positron emission tomography for suspected prostate cancer relapse at our institution. Of these men 202 did not receive hormone or radiation therapy, underwent imaging with choline positron emission tomography and multiparametric magnetic resonance imaging, and were found to have disease recurrence...
July 20, 2016: Journal of Urology
Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Laura Evangelista, Gabriella Castoria, Luigi Mansi
Choline is a quaternary ammonium base that represents an essential component of phospholipids and cell membranes. Malignant transformation is associated with an abnormal choline metabolism at a higher levels with respect to those exclusively due to cell multiplication. The use of Positron Emission Tomography/Computed Tomography (PET/CT) with radiocholine (RCH), labeled with (11) C or (18) F, is widely diffuse in oncology, with main reference to restaging of patients with prostate cancer. The enhanced concentration in neoplasm is based not only on the increasing growing rate, but also on more specific issues, such as the augmented uptake in malignant cells due to the up-regulation of choline kinase...
July 6, 2016: Journal of Cellular Physiology
Lijun Lu, Wenbing Lv, Jun Jiang, Jianhua Ma, Qianjin Feng, Arman Rahmim, Wufan Chen
PURPOSE: Radiomic features are increasingly utilized to evaluate tumor heterogeneity in PET imaging and to enable enhanced prediction of therapy response and outcome. An important ingredient to success in translation of radiomic features to clinical reality is to quantify and ascertain their robustness. In the present work, we studied the impact of segmentation and discretization on 88 radiomic features in 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and [(11)C]methyl-choline ([(11)C]choline) positron emission tomography/X-ray computed tomography (PET/CT) imaging of nasopharyngeal carcinoma...
June 20, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Sarah M Schwarzenböck, Matthias Eiber, Günther Kundt, Margitta Retz, Monique Sakretz, Jens Kurth, Uwe Treiber, Roman Nawroth, Ernst J Rummeny, Jürgen E Gschwend, Markus Schwaiger, Mark Thalgott, Bernd J Krause
PURPOSE: The aim of this study was to prospectively evaluate the value of [(11)C] Choline PET/CT in monitoring early and late response to a standardized first-line docetaxel chemotherapy in castration refractory prostate cancer (mCRPC) patients. METHODS: Thirty-two patients were referred for [(11)C] Choline PET/CT before the start of docetaxel chemotherapy, after one and ten chemotherapy cycles (or - in case of discontinuation - after the last administered cycle) for therapy response assessment...
June 17, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Tiziano Graziani, Francesco Ceci, Paolo Castellucci, Giulia Polverari, Giacomo Maria Lima, Filippo Lodi, Alessio Giuseppe Morganti, Andrea Ardizzoni, Riccardo Schiavina, Stefano Fanti
PURPOSE: To evaluate (11)C-choline PET/CT as a diagnostic tool for restaging prostate cancer (PCa), in a large, homogeneous and clinically relevant population of patients with biochemical recurrence (BCR) of PCa after primary therapy. The secondary aim was to assess the best timing for performing (11)C-choline PET/CT during BCR. METHODS: We retrospectively analysed 9,632 (11)C-choline PET/CT scans performed in our institution for restaging PCa from January 2007 to June 2015...
October 2016: European Journal of Nuclear Medicine and Molecular Imaging
Christian H Pfob, Sibylle Ziegler, Frank Philipp Graner, Markus Köhner, Sylvia Schachoff, Birgit Blechert, Hans-Jürgen Wester, Klemens Scheidhauer, Markus Schwaiger, Tobias Maurer, Matthias Eiber
PURPOSE: Positron emission tomography (PET) agents targeting the prostate-specific membrane antigen (PSMA) are currently under broad clinical and scientific investigation. (68)Ga-PSMA HBED-CC constitutes the first (68)Ga-labelled PSMA-inhibitor and has evolved as a promising agent for imaging PSMA expression in vivo. The aim of this study was to evaluate the whole-body distribution and radiation dosimetry of this new probe. METHODS: Five patients with a history or high suspicion of prostate cancer were injected intravenously with a mean of 139...
October 2016: European Journal of Nuclear Medicine and Molecular Imaging
Spencer C Behr, Rahul Aggarwal, Youngho Seo, Carina M Aparici, Emily Chang, Kenneth T Gao, Dora H Tao, Eric J Small, Michael J Evans
PURPOSE: The management of advanced or recurrent prostate cancer is limited in part by the lack of effective imaging agents. Metabolic changes in prostate cancer have previously been exploited for imaging, culminating in the recent US FDA approval of [(11)C]choline for the detection of subclinical recurrent disease after definitive local therapy. Despite this milestone, production of [(11)C]choline requires an on-site cyclotron, limiting the scope of medical centers at which this scan can be offered...
May 16, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Finn E von Eyben, Kalevi Kairemo
The objective of the systematic review and meta-analysis was to evaluate whether the choice between two radiotracers, (11)C-choline ((11)C-cho) and (18)F-fluorocholine ((18)F-FCH) for PET/CT, and different acquisition protocols contributed to detect metastases for patients with biochemical recurrence of prostate cancer after radical prostatectomy or radiotherapy. We searched in January 2016 in Pubmed and Embase for articles that had used radiolabeled choline PET/CT in restaging. The meta-analysis evaluated technical and clinical aspects...
July 2016: Annals of Nuclear Medicine
Ellen S Kim, Martin Satter, Marilyn Reed, Ronald Fadell, Arash Kardan
Glioblastoma multiforme (GBM) is the most common and lethal malignant glioma in adults. Currently, the modality of choice for diagnosing brain tumor is high-resolution magnetic resonance imaging (MRI) with contrast, which provides anatomic detail and localization. Studies have demonstrated, however, that MRI may have limited utility in delineating the full tumor extent precisely. Studies suggest that MR spectroscopy (MRS) can also be used to distinguish high-grade from low-grade gliomas. However, due to operator dependent variables and the heterogeneous nature of gliomas, the potential for error in diagnostic accuracy with MRS is a concern...
June 2016: Neuroradiology Journal
Alfred O Ankrah, Tjip S van der Werf, Erik F J de Vries, Rudi A J O Dierckx, Mike M Sathekge, Andor W J M Glaudemans
Tuberculosis has a high morbidity and mortality worldwide. Mycobacterium tuberculosis (Mtb) has a complex pathophysiology; it is an aerobic bacillus capable of surviving in anaerobic conditions in a latent state for a very long time before reactivation to active disease. In the latent tuberculosis infection, the individual has no clinical evidence of active disease, but exhibits a hypersensitive response to proteins of Mtb. Only some 5-10 % of latently infected individuals appear to have reactivation of tuberculosis at any one time point after infection, and neither imaging nor immune tests have been shown to predict tuberculosis reactivation reliably...
2016: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
Gurdip K Azad, Gary J Cook
There is growing evidence that molecular imaging of bone metastases with positron-emission tomography (PET) can improve diagnosis and treatment response assessment over current conventional standard imaging methods, although cost-effectiveness has not been assessed. In most cancer types, 2-[(18)F]-fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET is an accurate method for detecting bone metastases. For example, in breast cancer, combined (18)F-FDG-PET and computed tomography (CT) is more sensitive at detecting bone metastases than (99m)technetium (Tc)-labelled diphosphonate planar bone scintigraphy (BS) and there is increasing evidence to support the use of serial (18)F-FDG-PET for the assessment of osseous response to treatment...
July 2016: Clinical Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"